References
- PanagopoulosPMaltezosMHatzakisAParaskevisDHyperbilirubinemia in atazanavir treated HIV-infected patients: the impact of the UGT1A1*28 allelePharmgenomics Pers Med20171020520828790862
- GammalRSCourtMHHaidarCEClinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir PrescribingClin Pharmacol Ther201699436336926417955
- HorsfallLJZeitlynDTarekegnAPrevalence of clinically relevant UGT1A alleles and haplotypes in African populationsAnn Hum Genet201175223624621309756
- WHOGlobal Update AIDS 20162016Geneva, SwitzerlandWorld Health Organisation Available from: http://www.who.int/hiv/pub/arv/global-AIDS-update-2016_en.pdf?ua=1Accessed August 2, 2017
- OnoyaDNatteyCBudgellEPredicting the need for third-line antiretroviral therapy by identifying patients at high risk for failing second-line antiretroviral therapy in South AfricaAIDS Patient Care STDS201731520521228445088